Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Metrics to compare | SHPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSHPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.7x | −0.6x | |
PEG Ratio | 0.00 | 0.09 | 0.00 | |
Price/Book | 2.8x | 2.8x | 2.6x | |
Price / LTM Sales | - | 139.2x | 3.4x | |
Upside (Analyst Target) | - | 148.8% | 42.5% | |
Fair Value Upside | Unlock | 10.3% | 5.0% | Unlock |